Related Experiment Video

Updated: Jun 3, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

Pei-pei Dong1, Zhong-ze Fang, Yan-yan Zhang

  • 1Laboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, China.

Acta Pharmacologica Sinica
|March 5, 2011
PubMed
Abstract

Insights

Erlotinib inhibits CYP3A in a substrate-dependent manner, with time-dependent inhibition also observed. This time-dependent inhibition of CYP3A by erlotinib may contribute to drug-drug interactions, necessitating careful safety evaluations.

Area of Science:

  • Pharmacology and Drug Metabolism
  • Biochemistry
  • Medicinal Chemistry

Background:

  • Erlotinib is a targeted therapy drug used in cancer treatment.
  • Cytochrome P450 (CYP) enzymes play a crucial role in drug metabolism.
  • Understanding erlotinib's interaction with CYP enzymes is vital for predicting drug-drug interactions (DDIs).

Purpose of the Study:

  • To determine the effects of erlotinib on major Cytochrome P450 (CYP) isoforms.
  • To investigate the kinetics and amplitude of erlotinib-mediated CYP inhibition in human liver microsomes (HLMs).
  • To evaluate the potential for erlotinib to cause in vivo drug-drug interactions.

Main Methods:

  • Assessed the activity of seven major CYP isoforms (CYP1A2, CYP2A6, CYP3A, CYP2C9, CYP2D6, CYP2C8, CYP2E1) in HLMs.
  • Employed High-Performance Liquid Chromatography (HPLC) or Ultra-Fast Liquid Chromatography (UFLC) for activity analysis.
  • Utilized a two-step incubation method to examine the time-dependent inhibition of erlotinib on CYP3A.

Main Results:

  • Erlotinib inhibited CYP2C8 activity (IC50 = 6.17±2.0 μmol/L).
  • CYP3A inhibition by erlotinib was substrate-dependent (IC50 values for testosterone 6β-hydroxylation and nifedipine metabolism were 31.3±8.0 and 20.5±5.3 μmol/L, respectively).
  • Time-dependent inhibition of CYP3A by erlotinib was observed, with varying kinetic parameters (K(I) and k(inact)) depending on the probe substrate.

Conclusions:

  • Erlotinib exhibits both substrate-dependent and time-dependent inhibition of CYP3A.
  • The time-dependent inhibition of CYP3A by erlotinib is a potential mechanism for DDIs.
  • Clinical evaluation of erlotinib's safety, particularly in combination therapy, is warranted.

More Related Videos

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...